Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

a Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

James Berenson, MD, Laura Stampleman, MD, Alberto Bessudo, MD, Peter J Rosen, MD, Leonard M. Klein, MD, Thomas Woliver, MD, Marshall S. Flam, MD, Shahrooz Eshaghian, MD, Youram Nassir, MD, Swift A Regina, RN, Wang James, Eades Benjamin, PharmD, Tanya M. Spektor, PhD, Robert Vescio, MD

Blood (2015) 126 (23): 5383.

https://doi.org/10.1182/blood.V126.23.5383.5383

Published: 2015

Journal Articles

A Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma

James R. Berenson, MD, Laura V. Stampleman, MD, Alberto Bessudo, MD, Peter J. Rosen, MD, Leonard M Klein, MD, Thomas Woliver, MD, Marshall S. Flam, MD, Shahrooz Eshaghian, MD, Youram Nassir, MD, Regina A. Swift, RN, Robert Vescio, MD

Blood (2014) 124 (21): 4774.

https://doi.org/10.1182/blood.V124.21.4774.4774

Published: 2014

Journal Articles

Phase 1 Study Of Investigational Agent MLN8237 (Alisertib) + Rituximab ± Vincristine In Patients (Pts) With Relapsed/Refractory (Rel/Ref) Aggressive B-Cell Lymphomas

Kevin R. Kelly, MD, PhD, Daniel O. Persky, MD, Daruka Mahadevan, MD, PhD, Thomas P. Miller, MD, Soham D. Puvvada, MD, Kevin McDonagh, MD, John Hayslip, MD, Steven I. Park, MD, Jia Ruan, MD, PhD, Peter J. Rosen, MD, Swaminathan Padmanabhan Iyer, MD, MB, BS, Alexandra Stefanovic, MD, Bin Zhang, ScD, Xiaofei Zhou, PhD, Claudio Dansky Ullmann, MD, E. Jane Leonard, MSc, Jonathan W. Friedberg, MD

Blood (2013) 122 (21): 3027.

https://doi.org/10.1182/blood.V122.21.3027.3027

Published: 2013

Journal Articles

A Phase 2 Study Of Single-Agent Brentuximab Vedotin For Front-Line Therapy Of Hodgkin Lymphoma In Patients Age 60 Years and Above: Interim Results

Christopher A. Yasenchak, MD, Robert Chen, MD, Jeff P. Sharman, MD, Ralph V. Boccia, MD, Beata Holkova, MD, Peter J. Rosen, MD, Jonathan W. Friedberg, MD, Megan M. O'Meara, MD, Andres Forero-Torres, MD

Blood (2013) 122 (21): 4389.

https://doi.org/10.1182/blood.V122.21.4389.4389

Published: 2013

Journal Articles

Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin For Patients With Relapsed/Refractory Multiple Myeloma: Results From a Phase 1/2 Trial

James R. Berenson, MD, James D. Hilger, Ph.D., Leonard Klein, MD, Alberto Bessudo, MD, Peter J. Rosen, MD, Shahrooz Eshaghian, MD, Youram Nassir, MD, Regina A. Swift, RN, Robert Vescio, MD

Blood (2013) 122 (21): 3218.

https://doi.org/10.1182/blood.V122.21.3218.3218

Published: 2013

Journal Articles

2-O, 3-O Desulfated Heparin (ODSH) May Mitigate Chemotherapy-Induced Thrombocytopenia and Neutropenia in Patients Treated with Combination Gemcitabine (G)/Nab-Paclitaxel (A), a Myelosuppressive Chemotherapy Regimen

Darren Sigal, MD, Stephen Marcus, MD, Steven J. Cohen, MD, Peter J. Rosen, MD, Tim Nguyen, MD, Thomas Gribbin, MD, Pedro M. Quintana Diez, MD, Mitesh Borad, MD

Blood (2012) 120 (21): 4723.

https://doi.org/10.1182/blood.V120.21.4723.4723

Published: 2012

Journal Articles

Long-Term Efficacy and Safety Results From a Phase II Study of Ruxolitinib in Patients with Polycythemia Vera

Srdan Verstovsek, MD, PhD, Francesco Passamonti, MD, Alessandro Rambaldi, MD, Giovanni Barosi, MD, Peter J. Rosen, MD, Shui He, PhD, Nancy Contel, DVM, Bijoyesh Mookerjee, MD, FACP, Elisa Rumi, MD, Elisabetta Gattoni, MD, Lisa Pieri, MD, Mario Cazzola, MD, Hagop M. Kantarjian, MD, Tiziano Barbui, MD, Alessandro M. Vannucchi, MD

Blood (2012) 120 (21): 804.

https://doi.org/10.1182/blood.V120.21.804.804

Published: 2012

Journal Articles

Response to High Dose Cytarabine (HIDAC) As First Salvage for Relapsed Acute Lymphocytic Leukemia in Patients Receiving HIDAC As Initial Therapy

Anjali S. Advani, MD, Holly Gundacker, Nolyn Nyatanga, MD, Paul Elson, Peter J. Rosen, MD, Jennifer Bates, BS, CCRP, Mikkael A. Sekeres, MD, MS, Matt Kalaycio, MD, Ronald Sobecks, MD, Edward Copelan, MD, Frederick R. Appelbaum, MD

Blood (2011) 118 (21): 2594.

https://doi.org/10.1182/blood.V118.21.2594.2594

Published: 2011

Journal Articles

Durable Responses with the JAK1/ JAK2 Inhibitor, INCB018424, In Patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory or Intolerant to Hydroxyurea (HU)

Blood (2010) 116 (21): 313.

https://doi.org/10.1182/blood.V116.21.313.313

Published: 2010

Journal Articles

Measuring the Ability of Primary-Care Physicians To Diagnose and Manage Patients with Hematologic Malignancies.

Peter J. Rosen, MD, Richard C. Wender, MD, Haleh Kadkhoda, Scott L. Kober

Blood (2007) 110 (11): 3312.

https://doi.org/10.1182/blood.V110.11.3312.3312

Published: 2007

Journal Articles

A Phase 2 Study of Bortezomib in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL).

Sven de Vos, MD, PhD, Donna Fernando, MAOM, David P. Schenkein, MD, Peter J. Rosen, MD

Blood (2005) 106 (11): 4746.

https://doi.org/10.1182/blood.V106.11.4746.4746

Published: 2005

NARROW

a Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

A Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma

Phase 1 Study Of Investigational Agent MLN8237 (Alisertib) + Rituximab ± Vincristine In Patients (Pts) With Relapsed/Refractory (Rel/Ref) Aggressive B-Cell Lymphomas

A Phase 2 Study Of Single-Agent Brentuximab Vedotin For Front-Line Therapy Of Hodgkin Lymphoma In Patients Age 60 Years and Above: Interim Results

Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin For Patients With Relapsed/Refractory Multiple Myeloma: Results From a Phase 1/2 Trial

2-O, 3-O Desulfated Heparin (ODSH) May Mitigate Chemotherapy-Induced Thrombocytopenia and Neutropenia in Patients Treated with Combination Gemcitabine (G)/Nab-Paclitaxel (A), a Myelosuppressive Chemotherapy Regimen

Long-Term Efficacy and Safety Results From a Phase II Study of Ruxolitinib in Patients with Polycythemia Vera

Response to High Dose Cytarabine (HIDAC) As First Salvage for Relapsed Acute Lymphocytic Leukemia in Patients Receiving HIDAC As Initial Therapy

Durable Responses with the JAK1/ JAK2 Inhibitor, INCB018424, In Patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory or Intolerant to Hydroxyurea (HU)

Measuring the Ability of Primary-Care Physicians To Diagnose and Manage Patients with Hematologic Malignancies.

A Phase 2 Study of Bortezomib in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only